Castle Biosciences (CSTL) Accumulated Depreciation & Amortization (2018 - 2025)
Historic Accumulated Depreciation & Amortization for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to $16.8 million.
- Castle Biosciences' Accumulated Depreciation & Amortization rose 4674.51% to $16.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.8 million, marking a year-over-year increase of 4674.51%. This contributed to the annual value of $12.8 million for FY2024, which is 5821.72% up from last year.
- As of Q3 2025, Castle Biosciences' Accumulated Depreciation & Amortization stood at $16.8 million, which was up 4674.51% from $15.5 million recorded in Q2 2025.
- In the past 5 years, Castle Biosciences' Accumulated Depreciation & Amortization ranged from a high of $16.8 million in Q3 2025 and a low of $867000.0 during Q2 2021
- Its 5-year average for Accumulated Depreciation & Amortization is $7.9 million, with a median of $7.3 million in 2022.
- Per our database at Business Quant, Castle Biosciences' Accumulated Depreciation & Amortization surged by 67047.29% in 2022 and then tumbled by 580.84% in 2023.
- Quarter analysis of 5 years shows Castle Biosciences' Accumulated Depreciation & Amortization stood at $3.0 million in 2021, then skyrocketed by 157.99% to $7.8 million in 2022, then grew by 3.35% to $8.1 million in 2023, then skyrocketed by 58.22% to $12.8 million in 2024, then soared by 31.22% to $16.8 million in 2025.
- Its Accumulated Depreciation & Amortization was $16.8 million in Q3 2025, compared to $15.5 million in Q2 2025 and $14.2 million in Q1 2025.